



Final Appraisal Recommendation

Advice No: 1214 – June 2014

Velaglucerase alfa (VPRIV®) 400 units powder for solution for infusion

Submission by Shire Pharmaceuticals Ltd

Recommendation of AWMSG

Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 571), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Shire Pharmaceuticals Ltd
Date of first issue	June 2014
Last reviewed	September 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1214:
Velaglucerase alfa (VPRIV®) 400 units powder for solution for infusion. June 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.